Cifrazol: Main Uses and Benefits

Cifrazol is primarily used for the dietary management of patients with specific nutritional needs. The product is applied across domains where additional symptomatic support is needed, with relevance in contexts involving heightened systemic burden or temporary physiological imbalance. This includes managing acute symptomatic discomfort, episodic and fluctuating symptoms, and supportive relief for functional strain.

---

Relief for Symptomatic Discomfort

The product is relevant in contexts marked by increased discomfort or tension, helping to address symptom clusters that may become intense or disruptive. It may assist with easing the overall symptom load linked to symptoms related to systemic imbalance. It is often used when symptoms intensify and supportive relief is needed.

“This support helps patients cope more steadily when symptoms are more noticeable.”

Quick Fact: Relevant for Symptomatic Support

---

Managing Episodic Symptoms

Cifrazol is commonly used across conditions characterized by periods of heightened symptoms or involving recurrent manifestations. It helps maintain a sense of stability when symptoms are more noticeable and contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

1. Official FDA-submitted labeling

Who Can and Cannot Use Cifrazol?

The population eligibility for Cifrazol (Colecalciferol/Folic Acid) is strictly defined by regulatory documents, outlining populations for whom use is permitted, restricted, or contraindicated.

Eligibility Scope

Category	Regulatory Statement (Official Labeling)
Populations for whom use is allowed	Patients with documented nutritional needs for increased folate and Vitamin D, such as those with confirmed deficiencies.
Populations for whom use is not recommended	Patients with severe renal impairment due to compromised metabolism of the Colecalciferol component.
Populations for whom use is contraindicated	Patients with known hypersensitivity to any component. Contraindicated in individuals diagnosed with Hypercalcemia, Hypervitaminosis D, or Malabsorption Syndrome.
Age-related Eligibility Rules	Pediatric use is determined by medical necessity under professional supervision, as no specific minimum age restriction is stated in the core prescription label.
Condition-Specific Eligibility Rules	Use is strictly restricted in patients with pernicious anemia or other B12 deficiencies, as the Folic Acid component may mask the deficiency and allow neurological damage to progress.
Pregnancy and Lactation Eligibility	Use is conditional and must be as directed by a physician. Caution is required during lactation as Vitamin D metabolites pass into human milk.

---

Eligibility Classification Summary

Official labeling defines non-eligibility through absolute contraindications (e.g., Hypervitaminosis D) and conditional use. Eligibility is limited based on comorbidities such as severe renal impairment (use not recommended) and B12 deficiency (use restricted).

Interactions with other medicines and products

Cifrazol is a combination product whose interaction profile is defined by its two components: Colecalciferol (Vitamin D3) and Folic Acid (Vitamin B9). All interactions are based on official government regulatory documents.

---

Documented Interaction Patterns

Category	Officially Documented Interacting Substances
Pharmacodynamic Risk	Vitamin D Analogs are contraindicated due to the risk of hypercalcemia, which is an additive effect. Thiazide Diuretics and Calcium supplements also increase this hypercalcemia risk. Cardiac Glycosides (e.g., Digitalis) effects may be potentiated.
Exposure-Altering / PK	Anticonvulsants (e.g., Phenytoin, Phenobarbital) may increase the catabolism of the Colecalciferol component, leading to reduced exposure. Corticosteroids may also reduce the overall effect of Colecalciferol.
Reduced Efficacy	Dihydrofolate Reductase Inhibitors (e.g., Methotrexate) are documented to reduce the expected therapeutic effect of the Folic Acid component.

---

Administration Constraints

Specific administration constraints exist for substances that interfere with gastrointestinal absorption. Bile Acid Sequestrants (e.g., Cholestyramine, Colestipol) and Mineral Oil are documented to decrease the absorption of Colecalciferol. Therefore, the Colecalciferol component requires a mandatory separation of administration from these substances, as specified in regulatory labeling.

Molecular and Cellular Signaling via VDR Agonism

Cifrazol's active form (Calcitriol) functions as a high-affinity ligand for the intracellular Vitamin D Receptor (VDR), a type of nuclear receptor. Upon binding, this complex heterodimerizes with the Retinoid X Receptor (RXR) and translocates to the cell nucleus, where it binds to Vitamin D Response Elements (VDREs). This action regulates the transcription of target genes, thereby altering the synthesis of various proteins.

---

Systemic Homeostasis and Pleiotropic Regulation

In addition to genomic effects, Cifrazol engages rapid non-genomic signaling via membrane-associated VDRs, triggering swift internal cellular changes through second messengers (like calcium and cAMP). The VDR-mediated modulation primarily targets cells in the gut and kidney, promoting the expression of proteins necessary for the absorption of calcium and phosphorus while suppressing Parathyroid Hormone (PTH) levels. This cascade results in the physiological consequence of elevated and stabilized serum calcium and phosphorus concentrations, alongside the modulation of cell differentiation, proliferation, and immunological responses.

Cifrazol is an oral combination medicine intended for administration by mouth. The standardized regimen is the use of one capsule daily, a dosage that delivers 1 milligram of Folic Acid and 3,775 International Units (IU) of Colecalciferol. This regimen establishes a consistent, once-per-day schedule for introducing both essential vitamins into the patient's system.

For proper usage, the medicine is typically incorporated into the daily routine and often administered with or following a meal. This timing consideration supports the optimal absorption of the Colecalciferol (Vitamin D3) component, which is fat-soluble. Consistent adherence to the daily frequency is the governing principle of the treatment protocol.

As a prescription product, the medicine’s administration must occur under the supervision of a licensed medical practitioner. Its usage pattern is designed for long-term dietary management tailored to address unique or ongoing nutritional needs, rather than being limited to a short-term course of therapy. The product is used for specific patient populations, including women of childbearing age, pregnant women, and lactating mothers, though safety and effectiveness in pediatric patients are not established. When taking Cifrazol, patients are instructed not to exceed the recommended daily dose and should ensure that administration is separated by at least two hours from certain other medications that could interfere with absorption.

Cifrazol: Recent Clinical Evidence

---

Evidence for use in Indication A

Research has explored Cifrazol for use in people with Indication A, a condition marked by functional limitations and characterized by fluctuating or episodic manifestations. Studies conducted for this indication have typically been trials examining short-term symptom changes over defined time intervals. The research describes patterns that were observed in some studies related to outcomes related to physical discomfort and how outcomes reflecting daily functioning or activity level evolved during the study period. However, the evidence is limited regarding the long-term patterns observed, as follow-up durations were limited in many of the initial trials. The results apply only to the populations studied, and comparative evidence is lacking.

---

Evidence for use in Indication B

Cifrazol was evaluated in studies focusing on Indication B, which is a condition involving periods of heightened symptoms and associated with acute or disruptive episodes. The research in this area typically involved trials designed to monitor changes in outcomes describing episodic or acute changes and outcomes capturing phases of heightened symptom activity. The research describes patterns related to these outcomes, with studies focusing on episodes where symptoms become more noticeable. While some studies contribute to understanding symptom patterns related to functional imbalance, it is noted that findings were mixed across various measures, suggesting that evidence quality varies across studies.

---

What is Still Uncertain About Cifrazol

The current body of research contains gaps that require further exploration. Data for certain groups remain insufficient; for instance, there is limited information on how Cifrazol was evaluated in children or pregnancy-related populations. Furthermore, long-term outcomes are not fully established, and it is not yet clear what the full range of experiences is for people who use Cifrazol for many years. Research is ongoing to address these open questions and provide a more complete view of Cifrazol’s place in the broader evidence landscape.

Common questions about Cifrazol (FAQ)

Q: How quickly does Cifrazol usually start working?

A: According to official product information, the vitamin D component of Cifrazol requires a time lag of typically 10 to 24 hours to begin its action in the body. This delay is due to the necessity of the body to synthesize the active forms of the vitamin in the liver and kidneys.

Q: Are there any common over-the-counter medicines that should be avoided while using Cifrazol?

A: Official guidance suggests separating the administration of Cifrazol by at least two hours from antacids to avoid interference with the absorption of the medicine. The concurrent use of calcium supplements is also associated with an increased risk of developing hypercalcemia, which is a condition involving high calcium levels.

Q: Is it true that Cifrazol can cause tiredness or sleepiness?

A: Official documentation lists side effects such as weakness and dizziness, which may affect normal activity levels. Additionally, in some cases involving higher doses of Folic Acid, potential changes to sleep patterns have been noted.

Q: What are the most commonly reported less serious side effects of Cifrazol?

A: The official safety profile notes that gastrointestinal disturbances, such as nausea and constipation, are adverse reactions. The documented adverse reactions are typically classified as rare or of unknown frequency in regulatory materials.

Q: Is Cifrazol appropriate for use in children?

A: According to the official labeling, the safety and effectiveness of Cifrazol in pediatric patients are not established. As with any prescription product, use in children requires the guidance of a healthcare professional.

Q: Why is Cifrazol sometimes prescribed instead of drug Y?

A: Cifrazol is classified as a prescription combination product designed to address specific, compounded nutritional requirements. Its distinct purpose is to simultaneously provide the necessary Colecalciferol (Vitamin D3) and Folic Acid (Vitamin B9) input.

Q: Is Cifrazol known to cause stomach problems like nausea or upset stomach?

A: Yes, official safety information indicates that gastrointestinal disorders are possible adverse reactions associated with Cifrazol. These can include issues like nausea and constipation.

Q: Does Cifrazol interact with antacids or heartburn medication?

A: Official drug interaction information describes that the administration of Cifrazol is typically separated by at least two hours from antacids to prevent interference with its absorption. Combining the medicine with calcium supplements may also carry a risk of hypercalcemia.

Q: Is it normal to feel dizzy when first starting Cifrazol?

A: Dizziness is listed in the official safety information as a possible adverse reaction. Patients who experience dizziness are advised to notify their healthcare provider.

Q: Does Cifrazol come in different strengths or forms (e.g., tablet, liquid)?

A: Official labeling for Cifrazol describes the medicine as being available in multiple oral dosage forms. These can include a capsule, a tablet, and liquid drops.

Q: Are there any known interactions between Cifrazol and alcohol?

A: Regulatory information indicates that alcohol consumption may reduce the absorption of the Folic Acid component. Excessive alcohol use is noted to potentially increase the elimination of Folic Acid.

Q: Can Cifrazol change the results of standard lab blood tests?

A: Yes, Cifrazol can affect laboratory results by promoting the elevation of serum calcium and phosphate levels. The Folic Acid component is noted to potentially mask the hematological signs of a Vitamin B12 deficiency.

Q: Are headaches a common side effect of Cifrazol?

A: Headache is listed in the official safety information as a possible adverse reaction. Patients who experience a headache are advised to notify their healthcare provider.

Q: Is it possible for Cifrazol to cause a skin rash?

A: Yes, official safety information indicates that reactions related to the immune system have been reported with the Folic Acid component. These types of reactions can manifest as a skin rash or allergic sensitization.

Q: What is the usual duration of a course of Cifrazol?

A: Cifrazol is designed for long-term dietary management and nutritional support. Its intended purpose means it is not typically limited to a short, finite course of therapy.

Q: Why do official materials refer to Cifrazol's use as 'adjunctive' or 'supplementary'?

A: Official materials describe Cifrazol as belonging to the nutritional supplement class and a combination medicine. It is designed to provide supplementary input of specific essential vitamins to meet documented needs, reflecting its role as an addition to existing dietary intake.

Q: Are there any specific lifestyle changes mentioned to support Cifrazol use?

A: Official administration guidelines state it should be taken with or following a meal. Also, a healthcare provider may advise on changes to alcohol consumption and dietary calcium intake based on individual needs.

Q: What is the risk of dependence or tolerance with Cifrazol?

A: Cifrazol is classified as a vitamin combination and nutritional supplement. According to official documentation, it is not listed as a scheduled or controlled substance, which are the classes of medicines typically associated with dependence and tolerance risk.

Q: Are there any official restrictions on driving or operating machinery while using Cifrazol?

A: The official label does not contain a specific restriction against driving or operating machinery. However, the label does list side effects such as dizziness and weakness, which are conditions that can affect the ability to drive or operate machinery.

Cifrazol capsules must be stored at controlled room temperature, which is defined by the FDA as between 15 C and 30 C (59 F and 86 F). The medicine must be kept in a cool dry place to protect it from heat and moisture. Storage outside of this range is prohibited.

It is an explicit regulatory requirement that patients KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.

The official labeling for Cifrazol does not contain specific instructions for discarding unused or expired product. When no specific disposal instructions are given, the FDA generally advises utilizing a community drug take-back program or mixing the drug with an undesirable substance before discarding it in the household trash.